RT @Nocebo88: Sadly the wide use drugs without evidence is not a new phenomenon. We've shown in 2016 that #eculizumab, a very expensive dru…
Sadly the wide use drugs without evidence is not a new phenomenon. We've shown in 2016 that #eculizumab, a very expensive drug for rare diseases, was being widely used in France in organ #transplantation without any formal proof of efficacy. https://t.co/
RT @Nocebo88: "Off-label use of the expensive #orphandrug eculizumab (Soliris®) in France 2009–2013 and the impact of literature: focus on…
RT @Nocebo88: "Off-label use of the expensive #orphandrug eculizumab (Soliris®) in France 2009–2013 and the impact of literature: focus on…
RT @Nocebo88: "Off-label use of the expensive #orphandrug eculizumab (Soliris®) in France 2009–2013 and the impact of literature: focus on…
RT @claudiavaca5: Aquí con @TatianaAndia recordando que eres de la comunidad epistémica y que los primeros y arcaicos pasos en la discusión…
Aquí con @TatianaAndia recordando que eres de la comunidad epistémica y que los primeros y arcaicos pasos en la discusión del uso off label fueron en tu paso por @CIMUNCOL y con el profe @julianlopezUN
RT @Nocebo88: "Off-label use of the expensive #orphandrug eculizumab (Soliris®) in France 2009–2013 and the impact of literature: focus on…
RT @Nocebo88: "Off-label use of the expensive #orphandrug eculizumab (Soliris®) in France 2009–2013 and the impact of literature: focus on…
"Off-label use of the expensive #orphandrug eculizumab (Soliris®) in France 2009–2013 and the impact of literature: focus on the transplantation field" Full text (legal) link. https://t.co/sw04PEwDmn
RT @claudiavaca5: Off-label use of the expensive orphan drug eculizumab in France 2009-2013 https://t.co/SJTJhPm0B9 Johann Castañeda-Sanabr…
RT @claudiavaca5: Off-label use of the expensive orphan drug eculizumab in France 2009-2013 https://t.co/SJTJhPm0B9 Johann Castañeda-Sanabr…
RT @claudiavaca5: Off-label use of the expensive orphan drug eculizumab in France 2009-2013 https://t.co/SJTJhPm0B9 Johann Castañeda-Sanabr…
Off-label use of the expensive orphan drug eculizumab in France 2009-2013 https://t.co/SJTJhPm0B9 Johann Castañeda-Sanabria, orgullo docente